UNSPSC 51322006: Colesevelam hydrochloride

This classification denotes an anti-lipidemic agent with the molecular formula (C13H27N)n.(C12H27ClN2)n.(C9H18N2O)n.(C3H7N)n. ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P4SG24WI5Q, chemically known as 1-hexaminium, n,n,n-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-4-amine and n-2-propenyl-1-decanamine, hydrochloride but more generally known as colesevelam hydrochloride, which bears US NIH Compound Identifier 160051.

UNSPSC 51322006 Colesevelam hydrochloride is a Commodity code that covers a specific pharmaceutical active ingredient used in prescription medications. State and local governments procure colesevelam hydrochloride primarily through two channels: direct medication supply contracts for emergency services and public health programs, and cooperative purchasing agreements for generic pharmaceuticals distributed across multiple jurisdictions. The City of Tampa's Fire Rescue department exemplifies the first pathway, soliciting advanced life support medications as finished pharmaceutical products; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) exemplifies the second, aggregating generic pharmaceutical sourcing across state and local facilities in Minnesota and Oregon. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing organizations. Recent activity shows both direct municipal procurement and coordinated multi-jurisdictional purchasing models.

Activity concentrates in Florida, Texas, and Minnesota based on recent opportunities. The City of Tampa issued an IFB (Bid No. 26P00188) due April 8, 2026, for advanced life support medications with an estimated contract value of $40,000 and a one-year term plus renewal options. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in late March 2026 to explore direct-to-manufacturer prescription programs, signaling upstream market interest in pharmaceutical sourcing models. MMCAP issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act standards; the contract term is two years with optional extensions, effective July 1, 2026. The Tampa procurement includes a Small Local Business Enterprise sheltered market with a 5 percent bid discount.